A clash is brewing between doctors and patients when it comes to treatment for sleep apnea in those with obesity, a new study ...

Eli Lilly’s LLY key top-line drivers are its GLP-1 medicines, Mounjaro for type II diabetes and Zepbound for obesity. Both ...

Eli Lilly's experimental obesity drug, eloralintide, helped some patients lose 11.5% of their body weight at 12 weeks in an ...

A new study found that weight-loss medications like Ozempic and Mounjaro are not as effective in a “real-world” setting ...

A study, which was published in The New England Journal of Medicine, found that tirzepatide (Zepbound) is more effective for ...

Novo Nordisk is making moves to retain its market share in the weight loss space after Eli Lilly's tirzepatide won a ...

Early-stage study results suggest that a single shot of the company’s therapy, which works differently than GLP-1 medicines, ...

A new clinical trial has revealed that tirzepatide (Zepbound) surpasses semaglutide (Wegovy) in promoting weight loss among ...

Options are emerging for the tens of millions of people who stop taking GLP-1 drugs because of side effects, cost or ...

The deal is Lilly’s second obesity tie-up in a week, after sinking up to $870 million into an agreement with Camurus to ...

The deal, which could be worth up to $870 million overall, will give Lilly access to a delivery technology that may help ...

who now have another treatment option for this sleep disorder,” according to a statement from the academy. But Zepbound is only for people with obesity and sleep apnea, the AASM noted.